Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 5/20 | 0.34 |
| ▸ | LMNA | P02545 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | HTT | P42858 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | FGF23 | Q9GZV9 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.31 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2717541 | 1.00 | USP2 (0.36) | USP2HPGDLMNAALDH1A1HTT | |
| SCHEMBL15445445 | 1.00 | USP2 (0.36) | USP2HPGDLMNAALDH1A1HTT | |
| SCHEMBL2717906 | 0.85 | MEN1 (0.34) | HPGDLMNAALDH1A1HTTTSHR | |
| SCHEMBL2718384 | 0.82 | POLB (0.32) | LMNAALDH1A1MAPTL3MBTL1 | |
| SCHEMBL2718388 | 0.82 | POLB (0.32) | LMNAALDH1A1MAPTL3MBTL1 | |
| SCHEMBL4092075 | 0.74 | USP2 (0.40) | USP2HPGDLMNAALDH1A1HTT | |
| SCHEMBL7021794 | 0.71 | FFAR1 (0.42) | HPGDLMNAALDH1A1MAPTTSHR | |
| SCHEMBL9586744 | 0.71 | CA2 (0.48) | LMNATSHRHSD17B10 | |
| SCHEMBL9615770 | 0.64 | TSHR (0.55) | LMNAALDH1A1MAPTTSHRHSD17B10 | |
| SCHEMBL29798255 | 0.64 | HPGD (0.43) | HPGDLMNAALDH1A1HTTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140031355-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2014-01-30 | — | — | US | disclosed |
| EP-2635565-A1 | 5 -CYANO-4, 6 -DIAMINOPYRIMIDINE OR 6 -AMINOPURINE DERIVATIVES AS PI3K- DELTA INHIBITORS | Amgen Inc. (US) | 2013-09-11 | — | — | EP | disclosed |
| WO-2012061696-A1 | 5 -CYANO-4, 6 -DIAMINOPYRIMIDINE OR 6 -AMINOPURINE DERIVATIVES AS PI3K- DELTA INHIBITORS | AMGEN INC. (US) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031355-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, SSB, MALT1 | USP2 2894/4885HPGD 1172/4885LMNA 2393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.